1921. |
1922. |
1923. |
1924. |
1925. |
1926. |
1927. |
1928. |
1929. Alkali-activated artificial aggregatesAnže Tesovnik, Ottosen Lisbeth M., Vilma Ducman, 2025, zaključena znanstvena zbirka raziskovalnih podatkov Povzetek: The dataset file contains measurements from macro- to micro-scale analyses of alkali-activated aggregates produced from biomass fly ash. It includes data on mechanical performance, microstructural characterization, and chemical and mineralogical composition. This dataset supports the findings presented in the article entitled "Carbonation of lightweight alkali-activated aggregates based on biomass fly ash: effect on microstructure and leaching behavior" (https://doi.org/10.1016/j.cscm.2025.e05014).
Ključne besede: measurements, alkali-activated materials, biomass ash, carbonation, artificial aggregates
Objavljeno v DiRROS: 16.06.2025; Ogledov: 585; Prenosov: 345
 Raziskovalni podatki (478,07 KB)
Gradivo ima več datotek! Več... |
1930. Remission of chronic urticaria in patients treated with omalizumabKlara Cvenkel, Mojca Bizjak, Julij Šelb, Mitja Košnik, 2024, izvirni znanstveni članek Povzetek: Introduction: This study examined the remission probability and duration in chronic spontaneous urticaria (CSU) patients resistant to second-generation H1-antihistamines (sgAHs) undergoing omalizumab treatment.
Methods: This is a retrospective observational study of 176 adult CSU patients exhibiting a significant pruritus component (≥ 8) of the weekly urticaria activity score (UAS7) despite four daily sgAH tablets and starting omalizumab treatment with 300 mg every 4 weeks. After excluding 13 nonresponders, we analyzed 163 omalizumab responders (mean age 51.8 years, 74.4% female). The intervals between applications were increased. Discontinuation was considered for patients that remained asymptomatic on a gradually reduced dosage (to 150 mg every 12 weeks) without sgAHs.
Results: Omalizumab discontinuation was possible in 25.8% (42/163). The duration of omalizumab treatment before remission ranged from 7 to 6 months. Twenty-one patients (50.0%) maintained complete remission until the end of the observation period (September 2021) for 8 to 68 months. Of the relapsed patients, 71.4% (15/21) effectively controlled CSU with sgAHs. Six patients (28.6%; 6/21) required omalizumab reintroduction after 6 to 40 months of remission, responding favorably.
Conclusions: The study shows that a quarter of severe CSU patients achieve long-term remission. In addition, sgAHs effectively
manage symptoms in a majority of relapsed cases, and those requiring omalizumab reintroduction respond favorably.
Ključne besede: urticaria, antihistamines, omalizumab, urticaria, remission, urticaria relapse
Objavljeno v DiRROS: 16.06.2025; Ogledov: 407; Prenosov: 236
 Celotno besedilo (537,92 KB)
Gradivo ima več datotek! Več... |
